Advanced search
Publication Cover
Biomarkers in Medicine Volume 3, 2009 - Issue 5
Submit an article Journal homepage
65
Views
1
CrossRef citations to date
0
Altmetric
Theme: Biomarkers: paving the way for better stratification in heart failure - Review

Cytokines and Matrix Metalloproteinases as Potential Biomarkers in Chronic Heart Failure

Rachael DeardorffDivision of Cardiothoracic Surgery,Medical University of South Carolina,Charleston, SC 29403,USA and Ralph H Johnson Veterans Affairs Medical Center,Charleston,SC,USA. View further author information
&
Francis G SpinaleDivision of Cardiothoracic Surgery,Medical University of South Carolina,Charleston, SC 29403,USA and Ralph H Johnson Veterans Affairs Medical Center,Charleston,SC,USA. Correspondence[email protected]
View further author information
Pages 513-523 | Published online: 08 Oct 2009

Bibliography

  • van Heerebeek L , BorbelyA, NiessenHWet al. : Myocardial structure and function differ in systolic and diastolic heart failure.Circulation113, 1966–1973 (2006).
  • Zile MR , BaicuCF, BonnemaDD: Diastolic heart failure: definitions and terminology.Prog. Cardiovasc. Dis.47, 307–313 (2005).
  • Zile MR , BaicuCF, GaaschWH: Diastolic heart failure – abnormalities in active relaxation and passive stiffness of the left ventricle.N. Engl. J. Med.350, 1953–1959 (2004).
  • Mehra VC , RamgolamVS, BenderJR: Cytokines and cardiovascular disease.J. Leukoc. Biol.78, 805–818 (2005).
  • Meldrum DR : Tumor necrosis factor in the heart.Am. J. Physiol.274, R577–R595 (1998).
  • Jansen J , van der PollT, LeviMet al.: Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-α antibody.J. Clin. Immunol.15, 45–50 (1995).
  • Prabhu SD : Cytokine-induced modulation of cardiac function.Circ. Res.95, 1140–1153 (2004).
  • Krown KA , PageMT, NguyenCet al. : Tumor necrosis factor α-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death.J. Clin. Invest.98, 2854–2865 (1996).
  • Aukrust P , UelandT, LienEet al. : Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.Am. J. Cardiol.83, 376–382 (1999).
  • Dibbs Z , ThornbyJ, WhiteBG, MannDL: Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials.J. Am. Coll. Cardiol.33, 1935–1942 (1999).
  • Rauchhaus M , DoehnerW, FrancisDPet al. : Plasma cytokine parameters and mortality in patients with chronic heart failure.Circulation102, 3060–3067 (2000).
  • Deswal A , PetersenNJ, FeldmanAM, YoungJB, WhiteBG, MannDL: Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).Circulation103, 2055–2059 (2001).
  • Ferrari R , BachettiT, ConfortiniRet al. : Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure.Circulation92, 1479–1486 (1995).
  • Tziakas D , ChalikiasG, ParissisJTet al. : Prolonged activation of tumor necrosis factor (TNF)-α and its soluble receptors in chronic heart failure patients both in the compensated and decompensated state. Interplay between their levels and metalloproteinase-3.Eur. Cytokine Netw.15, 231–239 (2004).
  • Finkel MS , OddisCV, JacobTD, WatkinsSC, HattlerBG, SimmonsRL: Negative inotropic effects of cytokines on the heart mediated by nitric oxide.Science257, 387–389 (1992).
  • Cain BS , MeldrumDR, DinarelloCAet al. : Tumor necrosis factor-α and interleukin-1β synergistically depress human myocardial function.Crit. Care Med.27, 1309–1318 (1999).
  • Frangogiannis NG , MendozaLH, LindseyMLet al. : IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury.J. Immunol.165, 2798–2808 (2000).
  • Wang P , WuP, SiegelMI, EganRW, BillahMM: IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells.J. Immunol.153, 811–816 (1994).
  • Moore KW , de Waal Malefyt R, Coffman RL, O‘Garra A: Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol.19, 683–765 (2001).
  • Nagase H , WoessnerJF Jr: Matrix metalloproteinases. J. Biol. Chem.274, 21491–21494 (1999).
  • Tyagi SC : Proteinases and myocardial extracellular matrix turnover.Mol. Cell. Biochem.168, 1–12 (1997).
  • Spinale FG : Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function.Physiol. Rev.87, 1285–1342 (2007).
  • Van Lint P , LibertC: Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation.J. Leukoc. Biol.82, 1375–1381 (2007).
  • Li YY , FeldmanAM, SunY, McTiernanCF: Differential expression of tissue inhibitors of metalloproteinases in the failing human heart.Circulation98, 1728–1734 (1998).
  • Webb CS , BonnemaDD, AhmedSHet al. : Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling.Circulation114, 1020–1027 (2006).
  • Lopez B , GonzalezA, QuerejetaR, LarmanM, DiezJ: Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure.J. Am. Coll. Cardiol.48, 89–96 (2006).
  • Noji Y , ShimizuM, InoHet al. : Increased circulating matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction.Circ. J.68, 355–360 (2004).
  • Frantz S , StorkS, MichelsKet al. : Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality.Eur. J. Heart Fail.10, 388–395 (2008).
  • Ahmed SH , ClarkLL, PenningtonWRet al. : Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.Circulation113, 2089–2096 (2006).
  • Martos R , BaughJ, LedwidgeMet al. : Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction.Circulation115, 888–895 (2007).
  • Sivasubramanian N , CokerML, KurrelmeyerKMet al. : Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor.Circulation104, 826–831 (2001).
  • Kawamura N , KubotaT, KawanoSet al. : Blockade of NF-κB improves cardiac function and survival without affecting inflammation in TNF-α-induced cardiomyopathy.Cardiovasc. Res.66, 520–529 (2005).
  • Liacini A , SylvesterJ, LiWQet al. : Induction of matrix metalloproteinase-13 gene expression by TNF-α is mediated by MAP kinases, AP-1, and NF-κB transcription factors in articular chondrocytes.Exp. Cell Res.288, 208–217 (2003).
  • Xie Z , SinghM, SinghK: Differential regulation of matrix metalloproteinase-2 and -9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1β.J. Biol. Chem.279, 39513–39519 (2004).
  • Sundararaj KP , SamuvelDJ, LiY, SandersJJ, Lopes-VirellaMF, HuangY: Interleukin-6 released from fibroblasts is essential for upregulation of matrix metalloproteinase-1 expression by u937 macrophages in coculture- crosstalking between fibroblasts and u937 macrophages exposed to high glucose.J. Biol. Chem.284, 13714–13724 (2009).
  • Stearns ME , KimG, GarciaF, WangM: Interleukin-10 induced activating transcription factor 3 transcriptional suppression of matrix metalloproteinase-2 gene expression in human prostate CPTX-1532 cells.Mol. Cancer Res.2, 403–416 (2004).
  • Wilson EM , GunasingheHR, CokerMLet al. : Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure.J. Card. Fail.8, 390–398 (2002).
  • Schwartzkopff B , FassbachM, PelzerB, BrehmM, StrauerBE: Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy.Eur. J. Heart Fail.4, 439–434 (2002).
  • Kelly D , KhanSQ, ThompsonMet al. : Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction.Eur. Heart J. doi:10.1093/eurheartj/ehn315 (2008) (Epub ahead of print).
  • George J , PatalS, WexlerD, RothA, ShepsD, KerenG: Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.Am. Heart J.150, 484–487 (2005).
  • Jordan A , RoldanV, GarciaMet al. : Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis.J. Intern. Med.262, 385–392 (2007).
  • Ohtsuka T , NishimuraK, KurataA, OgimotoA, OkayamaH, HigakiJ: Serum matrix metalloproteinase-3 as a novel marker for risk stratification of patients with nonischemic dilated cardiomyopathy.J. Card. Fail.13, 752–758 (2007).
  • Alla F , Kearney-SchwartzA, RadauceanuA, Das Dores S, Dousset B, Zannad F: Early changes in serum markers of cardiac extra-cellular matrix turnover in patients with uncomplicated hypertension and type II diabetes. Eur. J. Heart Fail.8, 147–153 (2006).
  • Munger MA , JohnsonB, AmberIJ, CallahanKS, GilbertEM: Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.Am. J. Cardiol.77, 723–727 (1996).
  • Radauceanu A , DuckiC, VirionJMet al. : Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure.J. Card. Fail.14, 467–474 (2008).
  • Mohler ER 3rd, SorensenLC, GhaliJKet al.: Role of cytokines in the mechanism of action of amlodipine: the PRAISE heart failure trial. Prospective Randomized Amlodipine Survival Evaluation.J. Am. Coll. Cardiol.30, 35–41 (1997).
  • Matsumori A , YamadaT, SuzukiH, MatobaY, SasayamaS: Increased circulating cytokines in patients with myocarditis and cardiomyopathy.Br. Heart J.72, 561–566 (1994).
  • Testa M , YehM, LeePet al. : Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension.J. Am. Coll. Cardiol.28, 964–971 (1996).
  • Prabhakar U , EirikisE, DavisHM: Simultaneous quantification of proinflammatory cytokines in human plasma using the LabMAP assay.J. Immunol. Methods260, 207–218 (2002).
  • Kelly D , KhanS, CockerillGet al. : Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction.Eur. J. Heart Fail.10, 133–139 (2008).
  • Altieri P , BrunelliC, GaribaldiSet al. : Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure.Eur. J. Clin. Invest.33, 648–656 (2003).
  • Rossignol P , CambillauM, BisseryAet al. : Influence of blood sampling procedure on plasma concentrations of matrix metalloproteinases and their tissue inhibitors.Clin. Exp. Pharmacol. Physiol.35, 464–469 (2008).
  • Wu CY , WuMS, ChiangEPet al. : Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.Clin. Cancer Res.13, 2054–2060 (2007).
  • Torre-Amione G , KapadiaS, BenedictC, OralH, YoungJB, MannDL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD).J. Am. Coll. Cardiol.27, 1201–1206 (1996).
  • Wang Y , ZhouY, MengL, LuX, OuN, LiX: Inflammatory mediators in Chinese patients with congestive heart failure.J. Clin. Pharmacol.49, 591–599 (2009).
  • Limas CJ , HasikidisC, IakovouJ, KroupisC, HaidaroglouA, CokkinosDV: Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy.Eur. J. Clin. Invest.33, 443–448 (2003).
  • Yamaoka M , YamaguchiS, OkuyamaM, TomoikeH: Anti-inflammatory cytokine profile in human heart failure: behavior of interleukin-10 in association with tumor necrosis factor-α.Jpn. Circ. J.63, 951–956 (1999).
  • Lommi J , PulkkiK, KoskinenPet al. : Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure.Eur. Heart J.18, 1620–1625 (1997).
  • Valgimigli M , CeconiC, MalaguttiPet al. : Tumor necrosis factor-α receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study.Circulation111, 863–870 (2005).
  • Tsutamoto T , HisanagaT, WadaAet al. : Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure.J. Am. Coll. Cardiol.31, 391–398 (1998).
  • Maeda K , TsutamotoT, WadaAet al. : High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure.J. Am. Coll. Cardiol.36, 1587–1593 (2000).
  • Hartford M , WiklundO, Mattsson HultenLet al.: C-reactive protein, interleukin-6, secretory phospholipase A2 group IIA and intercellular adhesion molecule-1 in the prediction of late outcome events after acute coronary syndromes.J. Intern. Med.262, 526–536 (2007).
  • Dunlay SM , WestonSA, RedfieldMM, KillianJM, RogerVL: Tumor necrosis factor-α and mortality in heart failure: a community study.Circulation118, 625–631 (2008).
  • Niethammer M , SieberM, von HaehlingSet al.: Inflammatory pathways in patients with heart failure and preserved ejection fraction.Int. J. Cardiol.129, 111–117 (2008).
  • Naito Y , TsujinoT, Lee-KawabataMet al. : Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction.Heart Vessels24, 181–186 (2009).
  • Portik-Dobos V , AnstadtMP, HutchinsonJ, BannanM, ErgulA: Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes.Diabetes51, 3063–3068 (2002).
  • Marin F , RoldanV, ClimentV, GarciaA, MarcoP, LipGY: Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?Stroke34, 1181–1186 (2003).
  • Prince HE : Biomarkers for diagnosing and monitoring autoimmune diseases.Biomarkers10(Suppl. 1), S44–S49 (2005).
  • Zucker S , HymowitzM, ConnerCet al. : Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications.Ann. NY Acad. Sci.878, 212–227 (1999).
  • El-Menyar AA : Cytokines and myocardial dysfunction: state of the art.J. Card. Fail.14, 61–74 (2008).
  • Hudson MP , ArmstrongPW, RuzylloWet al. : Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.J. Am. Coll. Cardiol.48, 15–20 (2006).
  • Mann DL , McMurrayJJ, PackerMet al. : Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).Circulation109, 1594–1602 (2004).
  • Anker SD , CoatsAJ: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.Int. J. Cardiol.86, 123–130 (2002).
  • Levine B , KalmanJ, MayerL, FillitHM, PackerM: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.N. Engl. J. Med.323, 236–241 (1990).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.